ATE273285T1 - Neue guanidin-derivate als zelladhäsion- inhibitoren - Google Patents

Neue guanidin-derivate als zelladhäsion- inhibitoren

Info

Publication number
ATE273285T1
ATE273285T1 AT00905022T AT00905022T ATE273285T1 AT E273285 T1 ATE273285 T1 AT E273285T1 AT 00905022 T AT00905022 T AT 00905022T AT 00905022 T AT00905022 T AT 00905022T AT E273285 T1 ATE273285 T1 AT E273285T1
Authority
AT
Austria
Prior art keywords
cell adhesion
formula
compounds
guanidine derivatives
adhesion inhibitors
Prior art date
Application number
AT00905022T
Other languages
German (de)
English (en)
Inventor
Anuschirwan Peyman
Jochen Knolle
Karl-Heinz Scheunemann
David William Will
Denis Carniato
Jean-Francois Gourvest
Thomas Gadek
Sarah Catherine Bodary
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE273285T1 publication Critical patent/ATE273285T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/16Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT00905022T 1999-02-13 2000-02-04 Neue guanidin-derivate als zelladhäsion- inhibitoren ATE273285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99102916A EP1028114A1 (en) 1999-02-13 1999-02-13 Novel guanidine derivatives as inhibitors of cell adhesion
PCT/EP2000/000895 WO2000047564A1 (en) 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion

Publications (1)

Publication Number Publication Date
ATE273285T1 true ATE273285T1 (de) 2004-08-15

Family

ID=8237555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905022T ATE273285T1 (de) 1999-02-13 2000-02-04 Neue guanidin-derivate als zelladhäsion- inhibitoren

Country Status (11)

Country Link
US (1) US6340679B1 (https=)
EP (2) EP1028114A1 (https=)
JP (1) JP4642242B2 (https=)
AT (1) ATE273285T1 (https=)
AU (1) AU768206B2 (https=)
CA (1) CA2371789C (https=)
DE (1) DE60012890T2 (https=)
ES (1) ES2225086T3 (https=)
IL (1) IL144725A0 (https=)
MX (1) MXPA01008072A (https=)
WO (1) WO2000047564A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
GEP20053477B (en) 1999-08-13 2005-03-25 Biogen Inc Cell Adhesion Inhibitors and Pharmaceutical Compositions Containing Them
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
AU2004287875B2 (en) * 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
ES2630406T3 (es) * 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
WO2009128934A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
EP2265124A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH08504194A (ja) 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
EP0767792A4 (en) 1994-06-29 2002-11-20 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
EP0762882A4 (en) 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
HUP9802675A3 (en) 1995-08-14 2000-09-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
KR20000022190A (ko) * 1996-06-28 2000-04-25 플레믹 크리스티안 인테그린 저해제로서의 페닐알라닌 유도체
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
IL137423A0 (en) 1998-01-23 2001-07-24 Aventis Pharma Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Also Published As

Publication number Publication date
ES2225086T3 (es) 2005-03-16
IL144725A0 (en) 2002-06-30
AU768206B2 (en) 2003-12-04
US6340679B1 (en) 2002-01-22
CA2371789C (en) 2009-04-14
EP1155003B1 (en) 2004-08-11
AU2669900A (en) 2000-08-29
EP1028114A1 (en) 2000-08-16
DE60012890D1 (de) 2004-09-16
DE60012890T2 (de) 2005-08-25
CA2371789A1 (en) 2000-08-17
WO2000047564A1 (en) 2000-08-17
JP2002536438A (ja) 2002-10-29
JP4642242B2 (ja) 2011-03-02
MXPA01008072A (es) 2002-07-30
EP1155003A1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
MY122269A (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronection receptor antagonists
ATE273285T1 (de) Neue guanidin-derivate als zelladhäsion- inhibitoren
BG104630A (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CA2225366A1 (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
MY133246A (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
EA200200121A1 (ru) Замещенные производные пурина в качестве ингибиторов клеточной адгезии
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
AU2001277752A1 (en) Calcium receptor antagonists
BR9917315A (pt) Composições medicinais para liberação imediata para uso oral
ATE360018T1 (de) Thienylalaninderivate als inhibitoren der zelladhäsion
ATE432934T1 (de) Neue guanidino derivate als zelladhäsionhemmer
AR030874A1 (es) Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso
TH65078A (th) อนุพันธ์ไพร์โรลิดีนออกซาไดอะโซล-และไทอะไดอะโซล
ATE524442T1 (de) Antiproliferative wirkstoffe
TW200607498A (en) Agents for prevention or treatment of diseases associated with endothelial hyperproliferation
TH64558A (https=)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties